James R. Wilentz, M.D.

Interventional Cardiology
James Wilentz

My professional interests lie in evidence-based interventional treatment of coronary, carotid and vascular disease. For me it has been gratifying to practice both consultative and interventional cardiology. This has allowed me not only to achieve a high level of technical proficiency, but also to really connect with patients and families, and to understand their concerns. On the clinical and research side, I continue to be active in the areas of coronary flow determination before stenting, carotid stenting, stroke prevention, new approaches to intermittent claudication, leg vessel stenting and atherectomy, and valvular heart disease treatment. Coming to Cornell as faculty allows me to interact with a team of excellent physicians all focused on the provision of the highest level of care to our patients.

Dr. Wilentz was born and raised in the New York area. He graduated Alpha Omega Alpha from the New York University School of Medicine after receiving his BA in English from Columbia University. He performed his Medicine residency and Hematology fellowship at Harvard's Peter Bent Brigham Hospital in Boston. He was a Cardiology fellow and attending at the Boston City Hospital where he was co-investigator on the first TIMI trial of clot-dissolving medication in acute myocardial infarction. After his Interventional Cardiovascular fellowship under Dr. Andreas Gruentzig, the originator of coronary balloon angioplasty, he became Associate Chief of the Catheterization Labs at Lenox Hill Hospital, and has directed the Interventional Cardiology Labs at Beth Israel and St. Luke's Roosevelt. Dr. Wilentz joined the full-time faculty at Weill Cornell Medical College – New York Presbyterian Hospital in 2011. He is a Fellow of the American Heart Association's Council on Clinical Cardiology, the American College of Cardiology and the Society for Cardiovascular Angiography and Intervention. Dr. Wilentz is the author of numerous publications on carotid and peripheral vascular disease interventions and has been an investigator on many trials of coronary and peripheral and carotid interventional devices and strategies.


Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.

* indicates this physician is no longer accepting new patients with this insurance plan.

  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Insurance Plan of NY (HIP)
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicaid
  • Medicare
  • Oscar
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Freedom]
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]


1.      TIMI Study Group  (Wilentz JR co-investigator, Boston University)  The Thrombolysis in Myocardial Infarction (TIMI) Trial. Phase I Findings. N Engl J Med 1985, 312:932-6.

2.      Hillis LD  Borer J  Braunwald E  Chesebro JH  Cohen LS  Dalen J  Dodge HT  Francis CK Knatterud G  Ludbrook P  Markis JE  Mueller H  Desvigne-Nickens P  Passamani ER  Powers ER Rao AK  Roberts R  Roberts WC  Ross A  Ryan TJ  Sobel BE  Williams DO  Zaret B and Co-Investigators [TIMI I]  (Wilentz JR co-investigator, Boston University)  High dose intravenous streptokinase for acute myocardial infarction:  preliminary results of a multicenter trial. J Am Coll Cardiol   1985, 6:957-62.

3.      *Wilentz JR  Sanborn TA  Haudenschild CC  Valeri CR  Ryan TJ  Faxon DP   Platelet accumulation in experimental angioplasty:  time course and relation to vascular injury. Circulation 1987, 75:636-42.

4.      Ellis SG  Roubin GS  Wilentz JR  Douglas JS Jr  King SB 3d   Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989, 117:777-82.

5.      Lembo NJ  Black AJ  Roubin GS  Wilentz JR  Mufson LH  Douglas JS Jr  King SB 3rd   Effect of pretreatment with aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol  1990, 65:422-6.

6.      Romanello PP  Moses JW  Wilentz JR  Schiffer MB  DePasquale NP   Acute myocardial infarction complicating percutaneous aortic valvuloplasty successfully treated by percutaneous coronary angioplasty. Am Heart J  1990, 119:953-5.

7.      Coplan NL  Shimony RY  Ioachim HL  Wilentz JR  Posner DH  Lipschitz A  Ruden RA  Bruno MS  Sherrid MV  Gaetz  H  Englard A  Kukin M  Packer M   Primary pulmonary hypertension associated with human immunodeficiency viral infection. Am J Med 1990, 89:96-9.

8.      Coplan NL  Morales MC  Romanello P  Wilentz JR  Moses JW   Exercise-related atrioventricular block:  influence of myocardial ischemia. Chest   1991, 100:1728-30

9.      Sacknoff DM  Coplan NL  Wilentz JR  Schiffer MB Bush M   Exercise-induced ST segment depression:  Relation to non-occlusive coronary spasm. Am Heart J  1992, 125:242-4

10.   Ambrose JA Torre SR Sharma SK Israel DH Monsen CE Weiss M Unterecker W Grunwald A Moses J Marshall J et. al. Adjunctive thrombolytic therapy for angioplasty in ischemic rest angina: results of a double-blind randomized pilot study (Wilentz JR  co-investigator, Lenox Hill Hospital). J Am Coll Cardiol  1992, 20:1197-204

11.   *Wilentz JR Fratellone P  Diagnosis of Stenosis in a Pulmonary Valve-Conduit Using an angioplasty Guide and Probing Catheter. Cathet Cardiovasc Diagn 1993, 29: 144-147

12.   Kjellgren O Wilentz JR Kaganovsky L Sherman W  Prolonged lntracoronary infusion of Streptokinase: An Alternative Pharmacologic Approach to Extensive Thrombus in a Native Coronary Artery.  Cathet Card Diag  1994,  33: 80-84

13.   Fuchs J Cannon CP for the TIMI 7 Investigators  (Wilentz JR Principal Investigator, Lenox Hill Hospital) Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial.  Circulation 1995,  92:727-33

14.   Bittl JA  Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study Investigators.  (Wilentz JR Principal Investigator, Beth Israel Medical Center).  Am Heart J 1995, 130(3 Pt 2):658-65

15.   Bittl JA  Strony J  Brinker JA  Ahmed WH  Meckel CR  Chaitman BR  Maraganore J  Deutsch E  Adelman B  Hirulog Angioplasty Study Investigators (Wilentz JR Principal Investigator, Beth Israel Medical Center).  Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina.  N Engl J Med 1995, 333:764-9

16.   *Wilentz JR Mishkel G McDermott D Ravi K Fox JT Reimers CD Outpatient Coronary Stenting Using the Femoral Approach with Vascular Sealing.  J Invas Cardiol 1999, 11: 709-717

17.   *Wilentz JR Mishkel G McDermott D Ravi K Fox JT Reimers CD Maydick S  Outpatient Coronary Stenting: Femoral Approach with Vascular Sealing.  Herz 1999, 24: 624 - 633

18.   *Wilentz J  Patel R  Kunchithapatham S   Rota-stenting of a calcified anomalous left coronary artery via the arm in a multi-vasculopathic patient   J Invasive Cardiol 2001, 13: 460-3

19.   The SEAL Trial Study Team (Wilentz JR Principal Investigator Beth Israel Medical Center) Assessment of the safety and efficacy of the DUETT vascular hemostasis device: Final results of the safe and effective vascular hemostasis (SEAL) trial.  American Heart Journal. 2002, 143:612-619

20.   *Wilentz JR Chati Z Krafft V Amor M  Retinal Embolization During Carotid Angioplasty and Stenting:  Mechanisms and Role of Cerebral Protection Systems  Catheter Cardiovasc Interv 2002, 56: 320-327

21.   Lee M  Singh V  Nero T  Wilentz JR  Cutting Balloon Angioplasty   J Invasive Cardiol 2002, 14:552-6

22.   Shteerman E Singh V Nero T Lee M Wilentz J Menon V. Images in cardiovascular medicine. Acute myocardial infarction in uncorrected tetralogy of fallot. Circulation. 2002 Jul 23;106(4):e13-4.

23.   Stone GW, Rogers C, Ramee S (Wilentz, JR Principal Investigator St. Luke’s Medical Center) Distal filter protection during saphenous vein graft stenting: Technical and clinical correlates of efficacy  J. Am. Coll. Cardiol.  2002;40;1882-1888

24.   Lee MS Nero T  Makkar RR  Wilentz JR.  Treatment of coronary aneurysm in acute myocardial infarction with AngioJet thrombectomy and JoStent coronary stent graft  J. Invas Cardiol 2004: 16:294–296

25.   Lee MS. David EM. Makkar RR. Wilentz JR. Molecular and cellular basis of restenosis after percutaneous coronary intervention: the intertwining roles of platelets, leukocytes, and the coagulation-fibrinolysis system. Journal of Pathology 2004 203:861-70

26.   Lee MS Wilentz JR, Makkar RR Singh V  Nero T Swistel D Belsey SJ Simon C Rametta S DeRose J Hybrid Revascularization Using Percutaneous Coronary Intervention and Robotically Assisted Minimally Invasive Direct Coronary Artery Bypass Surgery  J. Invas Cardiol 2004: 16: 419-425

27.   Lee MS, Rametta S, Aragon J, Khan A, Wilentz J, Singh V, Levitt H, Kamra A, Valania G, Makkar R. New heparin dosing regimen for diabetics undergoing percutaneous coronary intervention. J Invasive Cardiol. 2005 May;17(5):248-50. 

28.   Lee MS Singh V Wilentz JR Makkar R  Review: AngioJet Thrombectomy  J Invasive Cardiol 2004 16: 587 - 591

29.   Amor M  Eid-Lidt G  Chati Z  Wilentz J  Endovascular treatment of the subclavian artery: Stent implantation with or without predilatation  Catheter Cardiovasc Interv 2004, 63: 364-370

30.   Lee MS Makkar R Singh V Rametta S Valania G Platzman Z Wilentz J Pre-procedural Administration of Aminophylline Does Not Prevent AngioJet Rheolytic Thrombectomy-induced Bradyarrhythmias  J Invasive Cardiol 2005: 19 – 22

31.   DeRose JJ Jr, Balaram SK , Ro C, Swistel DG, Singh V, Wilentz JR, Todd GJ, Ashton RC Jr. Mid-term results and patient perceptions of robotically-assisted coronary artery bypass grafting. Interactive Cardiovascular and Thoracic Surgery 2005:406-411.

32.   Schneider L, Vitek J, Wilentz J, Iyer S, Roubin G Stenting the Critical Calyceal Carotid Bifurcation – a Technical Update Journal of Invasive Cardiology 2008;20:255–257.

33.   *Wilentz JR, Hecht HS. Utility of coronary computed tomography guidance for intervention of an anomalous right coronary artery. J Invasive Cardiol. 2009;21(7):374-6.

34.   *Wilentz JR. Revascularization for renal-artery stenosis. N Engl J Med. 2010; 25;362(8):762 (letter) author reply 763-4

35.   *Wilentz J In Haiti, a Lesson for U.S. Health Care. New York Times (Op-Ed) July 28 2010 accessed at: http://www.nytimes.com/2010/07/29/opinion/29wilentz.html



1.      *WilentzJR. Anatomy is destiny, but physiology is here today. J Invasive Cardiol. 2010;22(9):417-8

2.      *WilentzJR. Rotational atherectomy in the DES era - away go troubles down the drain? J Invasive Cardiol. 2011;23(1):33-4

3.      *WilentzJR. Renal arterial ultrasound - predictor of things to come? J Invasive Cardiol. 2011 Jun;23(6):232-3.


1.      Lieberman SM, Undemir C, Shaknovich A, Wilentz JR, Friedman MS, Higgins J, CohenNT, McCrossan J, Moses JW. Coronary Flow Reserve By Doppler Wire is Not Equivalent to Stenotic Flow Reserve. Circulation 1993;88 (Suppl. I) I-204.

2.      Meckel CR Kjelsberg MA Ahmed WH Ganz P Piana RN Deutsch E Strony J Bittl JA Hirulog Angioplasty Study Investigators (Wilentz JR Principal Investigator, Beth Israel Medical Center).  Bailout Stenting for Abrupt Closure During Coronary Angioplasty.  Circulation 1995 92: I-688

3.      Strony J Ahmed WH Meckel CR Maraganore J Adelman B Bittl JA  Hirulog Angioplasty Study Investigators  (Wilentz JR Principal Investigator, Beth Israel Medical Center).  Clinical Evidence for Thrombin Rebound After Stopping Heparin but not Hirulog  Circulation. 1995 92: I-609

4.      Ahmed WH Meckel CR Grines CL Strony J Borzak S Kraft PL Timmis GC Ferguson JJ Adelman B Bittl JA Hirulog Angioplasty Study Investigators (Wilentz JR Principal Investigator, Beth Israel Medical Center).  Relation Between Ischemic Complications and Activated Clotting Times During Coronary Angioplasty: Different Profiles for Heparin and Hirulog.  Circulation 1995 92: I-608

5.      *Wilentz JR Mishkel G Reimers C Ravi K Sherman W McDermott D Kupersmith A. Outpatient Stenting Using the Femoral Approach with Vascular Sealing. Am. J. Cardiol 1998 82 (7A):355

6.      Faxon DP  Buchbinder M  Cleman MW  Wilentz JR  Liprie SF  Mehra A  Petrovich Z  Popma JJ  Harrison L  Ricci N  Varkey J.  Intracoronary Radiation to Prevent Restenosis in Native Coronary Lesions:  The Results of the Pilot Phase of the ARREST Trial.  Abstract presented to ACC 48th Annual Scientific Session

7.      Sanborn TA Mooney MR Ellis SG Teirstein PS Wilentz JR  The Safe and Effective Artery Sealing (SEAL) Trial.  Initial results of the multicenter randomized trial.  Abstract presented to ACC 48th Annual Scientific Session

8.      Ellis S Mooney M  Silber S Teirstein P Rodriguez R Sanborn T Feldman T Pichard A Collins T  Wilentz J Gershony G  DUETT Fernoral Artery Closure Device vs Manual  Compression After Diagnostic or Interventional Catheterization: Results of the SEAL Trial.  Circulation 1999;100: I-513

9.      *Wilentz JR Mishkel G Reimers C Ravi K Sherman W McDermott D Kupersmith A.  Outpatient Stenting Using the Femoral Approach with Vascular Sealing. Am. J. Cardiol 1999 84 (6A):38P

10.   *Krafft V Chati Z Wilentz J Amor M Henry M.  Immediate retinal events following carotid angioplasty and stenting: Mechanisms and role of cerebral protection systems  Am. J. Cardiol. 2000 86 (8A): 29i

11.   *Wilentz JR Friday M.  Incidence And Degree Of Subclavian Stenosis In Patients Undergoing Left Internal Mammary Angiography  Catheter Cardiovasc Interv 2002 56:135

12.   Lee MS Singh V Rametta S Nero T Fox M Wilentz JR.  Diabetics achieve lower activated clotting time when given the same dose of heparin as non-diabetics during percutaneous coronary intervention  J Am Coll Cardiol 2003 41 (suppl A): 12A

Honors and Awards

Sept, 1981 - National Research Service Award, Public Health Service
June, 1976 - Alpha Omega Alpha, Delta Chapter, New York University School of Medicine